Trials
3 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ETX101 is a non-replicating, recombinant adeno-associated viral vector serotype 9 (rAAV9) comprising a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A). ETX101 is intended as a one-time intracerebroventricular (ICV) administration.”In the company’s words, NCT05419492 on ClinicalTrials.gov
- Tested for
- Dravet Syndrome (3 trials)
- Main trialPhase 1/2
- “ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1A), aged ≥48 months to \<18 years (Part 1B), and aged ≥6 to \<48 months (Part 2). Part 1A follows an open-label, dose-escalation design, Part 1B follows an open-label design, and Part 2 is a randomized, double-blind, sham delayed-treatment control study.”In the company’s words, NCT05419492 on ClinicalTrials.gov
Other drugs for Dravet Syndrome
- LP352Longboard Pharmaceuticals · Phase 3
- ZorevunersenStoke Therapeutics, Inc · Phase 3
- Clemizole HClEpygenix · Phase 3
- ION337Ionis Pharmaceuticals, Inc. · Phase 1/2
- BMB-101Bright Minds Biosciences · Phase 2
- CannabidiolJazz Pharmaceuticals · Marketed (Phase 4 trial)
Coming up3
- Jun 2028Phase 1/2 trial completes · ClinicalTrials.gov
- Sep 2030Phase 1/2 trial completes · ClinicalTrials.gov
- Oct 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Jun 2028 | A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome | |
| Phase 1/2Active, not recruiting | Sep 2030 | A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only) | |
| Phase 1/2Active, not recruiting | Oct 2030 | A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026